Please use this identifier to cite or link to this item:
Title: Hospital costs of nosocomial multi-drug resistant pseudomonas aeruginosa acquisition
Author: Morales Bartolomé, Eva
Cots Reguant, Francesc
Sala, María Luisa
Comas Serrano, Mercè
Belvis, Francesc
Riu, Marta
Salvadó, Margarita
Grau Cerrato, Santiago
Horcajada, Juan P.
Milagro Montero, Maria
Castells Oliveres, Xavier
Others: Universitat Oberta de Catalunya (UOC)
Keywords: antimicrobial resistance
economic analysis
hospital cost
multi-drug resistance
pseudomonas aeruginosa
Issue Date: 23-May-2012
Publisher: BMC Health Services Research
Citation: Morales, E., Cots Reguant, F., Sala, M.L., Comas, M., Belvis, F., Riu, M., Salvado, M., Grau, S., Horcajada, J.P. & Milagro Montero, M.(2012). Hospital costs of nosocomial multi-drug resistant pseudomonas aeruginosa acquisition. BMC Health Services Research, 12(1). doi: 10.1186/1472-6963-12-122
Also see:
Abstract: We aimed to assess the hospital economic costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. A retrospective study of all hospital admissions between January 1, 2005, and December 31, 2006 was carried out in a 420-bed, urban, tertiary-care teaching hospital in Barcelona (Spain). All patients with a first positive clinical culture for P. aeruginosa more than 48 h after admission were included. Patient and hospitalization characteristics were collected from hospital and microbiology laboratory computerized records. According to antibiotic susceptibility, isolates were classified as non-resistant, resistant and multi-drug resistant. Cost estimation was based on a full-costing cost accounting system and on the criteria of clinical Activity-Based Costing methods. Multivariate analyses were performed using generalized linear models of log-transformed costs.
Language: English
ISSN: 1472-6963MIAR
Appears in Collections:Articles

Files in This Item:
File Description SizeFormat 
costs.pdf275.33 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons